VASCULAR THERAPIES
Vascular Therapies (VT) is a biopharmaceutical company committed to the development and commercialization of innovative new treatments to address major unmet clinical needs of patients requiring a vascular access to support hemodialysis. Our lead product candidate, containing sirolimus, has received orphan drug designations in the U.S. and E.U. for the dialysis vascular access indications. The company was founded in 2001 and headquartered in Cresskill, New Jersey.
VASCULAR THERAPIES
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2001-01-01
Address:
Cresskill, New Jersey, United States
Country:
United States
Website Url:
http://www.vasculartx.com
Total Employee:
1+
Status:
Active
Contact:
(201) 266-8310
Email Addresses:
[email protected]
Total Funding:
89.96 M USD
Technology used in webpage:
U.S. Server Location
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
PanTheryx
PanTheryx is a nutrition and biotechnology company that utilizes the cellular and biomolecular processes of bovine colostrum.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Current Employees Featured
Founder
Investors List
CNF Investments, LLC
CNF Investments, LLC investment in Private Equity Round - Vascular Therapies
Savitr Capital
Savitr Capital investment in Venture Round - Vascular Therapies
Official Site Inspections
http://www.vasculartx.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Vascular Therapies"
Vascular Therapies | Improving Vascular Access
Vascular Therapies is improving vascular access by reducing surgical stenosis.See details»
About Vascular Therapies
Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogenâ„¢, an investigational sirolimus …See details»
Vascular Therapies - Crunchbase Company Profile & Funding
Vascular Therapies (VT) is a biopharmaceutical company committed to the development and commercialization of innovative new treatments to address major unmet clinical needs of …See details»
Vascular Therapies
Vascular Therapies is a privately held, biopharma company developing Sirogen, a proprietary sirolimus formulation for local, perivascular drug delivery. The goal of this therapeutic …See details»
Vascular Therapies - LinkedIn
Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogenâ„¢,...See details»
Vascular Therapies Completes Enrollment in the ACCESS 2
Aug 5, 2024 · Vascular Therapies, Inc. is a privately‑held, biotechnology company that is developing Sirogen, a sirolimus drug formulation for local, perivascular drug delivery. The goal …See details»
Vascular Therapies Completes $25 Million Private Financing - PR …
Mar 29, 2022 · Vascular Therapies is a privately held, biopharma company developing Sirogenâ„¢, a proprietary sirolimus formulation for local, perivascular drug delivery. The goal of this …See details»
Vascular Therapies Completes Enrollment in the ACCESS Study, a …
Aug 19, 2019 · Vascular Therapies, Inc. ("VT") is a privately‑held, biotechnology company that has developed a proprietary sirolimus formulation for local, perivascular drug delivery. The …See details»
Vascular Therapies completes $25 million private financing
Mar 29, 2022 · Vascular Therapies is a privately held, biopharma company developing SirogenTM, a proprietary sirolimus formulation for local, perivascular drug delivery. The goal of …See details»
Vascular Therapies - Craft
Vascular Therapies is a biopharmaceutical company that specializes in the treatments for patients requiring an AV fistula for dialysis.See details»
News - Vascular Therapies
Vascular Therapies, Inc. is a privately‑held, biotechnology company that is developing Sirogen, a sirolimus drug formulation for local, perivascular drug delivery. The goal of this therapeutic …See details»
Vascular Therapies Announces Positive Preliminary Clinical Results …
CRESSKILL, N.J., Sept. 9, 2019 /PRNewswire/ -- Vascular Therapies, a clinical stage biotechnology company, is developing Sirogenâ„¢, a proprietary sirolimus formulation for …See details»
Vascular Therapies - Overview, News & Similar companies
Vascular Therapies contact info: Phone number: (201) 266-8310 Website: www.vasculartx.com What does Vascular Therapies do? Vascular Therapies, Inc., is a privately held, biopharma …See details»
News - Vascular Therapies
Vascular Therapies is a privately held, biopharma company developing Sirogen TM, a proprietary sirolimus formulation for local, perivascular drug delivery. The goal of this therapeutic …See details»
Vascular Therapies Completes Upsized $17.3 Million Private …
Jan 28, 2020 · Vascular Therapies, Inc., is a privately-held biopharma company developing Sirogen, a proprietary sirolimus formulation for local, perivascular drug delivery. The goal of …See details»
Vascular Therapies Completes $25 Million Private Financing
Mar 29, 2022 · Vascular Therapies is a privately held, biopharma company developing Sirogenâ„¢, a proprietary sirolimus formulation for local, perivascular drug delivery. The goal of this …See details»
Vascular Therapies Announces Clinical Results From Its Phase 3 ...
Apr 29, 2021 · CRESSKILL, N.J.-- ( BUSINESS WIRE )--Vascular Therapies, a privately held biotechnology company is developing Sirogenâ„¢, a proprietary sirolimus formulation for …See details»
ACCESS 2 Clinical Study | An AV Fistula Trial - Vascular Therapies
Switching from your catheter to an AV fistula? Getting an AV fistula is an important step in your treatment journey. AV fistulas are the best access choice for hemodialysis according to the …See details»
Vascular Therapies Announces Presentation of Phase 3 Clinical …
CRESSKILL, N.J., Nov. 4, 2021 /PRNewswire/ -- Vascular Therapies, a privately held biotechnology company is developing Sirogen â„¢, a proprietary sirolimus formulation for …See details»
Vascular Therapies Inc. | Cresskill NJ - Facebook
Vascular Therapies Inc., Cresskill, New Jersey. 20 likes. Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing...See details»